Infant formula maker Bellamy’s Australia has said its ‘Australian label’ products sold through Australian retail, the daigou channel and China cross-border e-commerce “will not be impacted” by the firm missing a 2018 deadline to register some of its products for sale in China.
Bellamy’s said last week it would miss a 1 January 2018 deadline set by China Food and Drug Administration (CFDA) to register its infant formula products for exports for sale in the country – but that it was “confident” it would achieve registration at a later date.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
However, in an update for shareholders today (3 April), Bellamy’s said “product manufactured and imported to China prior to 1 January 2018 can continue to be sold in China after 1 January 2018 until shelf life expiry”.
Bellamy’s said in the update issued to the Australian Securities Exchange: “We are also actively working with our China offline distributor SIIC to preserve continuity of supply of our ‘Chinese label’ (or Peoples’ Republic of China) product during our registration process.”
